Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Northwest Biotherapeutics, Inc. (NWBO) had Free Cash Flow of $-9.51M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.38M |
|
$-19.61M |
|
-- |
|
$0.38M |
|
$17.69M |
|
$-17.31M |
|
$-2.03M |
|
$-19.34M |
|
$-19.34M |
|
$-19.34M |
|
$-19.34M |
|
$-19.34M |
|
$-19.34M |
|
$-17.31M |
|
$-16.54M |
|
1.36B |
|
1.36B |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$4.69M |
|
$16.29M |
|
$22.82M |
|
$27.50M |
|
$83.06M |
|
$13.04M |
|
$29.28M |
|
$112.34M |
|
$-99.48M |
|
$-86.76M |
|
$-84.84M |
|
1.39B |
|
| Cash Flow Statement Financials | |
$-9.42M |
|
$-0.09M |
|
$11.73M |
|
$2.17M |
|
$2.78M |
|
$0.60M |
|
$0.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.06 |
|
-- |
|
-- |
|
-0.18 |
|
-0.67 |
|
100.00% |
|
-4616.27% |
|
-4616.27% |
|
-- |
|
-5158.13% |
|
-5228.80% |
|
|
Free Cash Flow |
$-9.51M |
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
19.44% |
|
22.30% |
|
-70.33% |
|
26.94% |
|
$-0.06 |
|
$-0.01 |
|
$-0.01 |
|